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Summary
The T cell antigen receptor consists of the Ti a/a heterodimer which recognizes antigen, and
the associated CD3 chains, thought to be involved in signal transduction . To understand the
nature of'the interaction between Ti and CD3, chimeric molecules which included the 000H-
terminal segments of Ti a or 0 linked to the extracellular segment of CD8, were transfected
into a mutant T cell deficient in Tio chain expression and cell surface CD3. Both chimeric chains
were required to express the chimeric Ti and to restore CD3 surface expression . CD8/Ti and
CD3 cointernalized and coimmunoprecipitated . Stimulation of the chimeric receptor induced
transmembrane signaling events and cell activation. These results demonstrate that the Ti a and
0 COOH termini containing the transmembrane domains are sufficient for structural and functional
coupling of Ti to CD3 .
The structural and functional interactions of individualchains of polypeptides comprising oligomeric membrane
receptors are poorly understood . The TCR is a multi-chain
complex consisting of a disulfide-linked heterodimer (Ti) as-
sociated with at least five invariant chains (y, 8, e, and ~2),
which together constitute the CD3 complex (1-3) . On most
T cells, the Ti subunit consists of an a/(3 heterodimer, Ti
a/A which is responsible for the recognition of antigen in
the form of peptide fragments associated with MHC mole-
cules on the surface of antigen presenting cells (4, 5) . On
a small subpopulation of T cells, an alternative form of the
Ti subunit, Ti 'Y/S, is expressed in association with CD3
(6-8), although the antigen specificity ofTi y/6 has not been
definitively established. The CD3 chains are thought to couple
Ti to intracellular `signal transduction mechanisms that are
activated by TCR stimulation, including the phosphatidyl-
inositol pathway and a tyrosine kinase pathway (9, 10) . Struc-
turally, the longer cytoplasmic (CYT)t domains of CD3
(40-113 amino acids) compared with those of the Ti chains
(five amino acids) are more consistent with this signaling func-
tion for CD3 (1, 11) . Moreover, stimulation of CD3 with
mAbs mimics the effects ofthe binding of antigen or anti-Ti
mAbs to Ti in inducing signal transduction events and T cell
activation (9, 12, 13) .
Ti and CD3 are intimately associated on the plasma mem-
brane as demonstrated by a variety ofmethods . Ti and CD3
'Abbreviations used in this paper. CYT, cytoplasmic; EC, extracellular; ER,
endoplasmic reticulum ; IP, inositol phosphate; SFFV, Friend spleen focus-
forming viral; TM, transmembrane.
cointernalize in response to mAbs against either structure
(14) . Under appropriate conditions of solubilization, Ti and
CD3 can be coimmunoprecipitated (8, 15, 16) . They can also
be chemically crosslinked on unstimulated T cell lines (17, 18) .
Previous studies with somatic cell mutants have shown that
surface expression of CD3 is dependent on its proper assembly
with Ti a and 0 (19-21) and on 1'chain expression (22, 23) .
Our study was undertaken to define the domain(s) of the
Ti chains that are responsible for the structural and functional
association with CD3 . The varying ability of different deter-
gent concentrations to preserve the integrity ofthe TCR com-
plex during solubilization has suggested that the hydrophobic
transmembrane (TM) domains are important in Ti/CD3 as-
sociation (8) . Interestingly, the Ti and CD3 chains contain
unusually positioned, basic or acidic residues within their
otherwise hydrophobic TM domains. These amino acids
are highly conserved across species (1, 2, 24) . Ti a/a as well
as Ti y/S TM domains contain the basic amino acids lysine
and arginine, whereas the TM domains of CD3 contain
residues of the opposite charge, glutamate and asparate. It
has been proposed that these charged residues may be respon-
sible for Ti/CD3 interaction through the formation of salt
bridges (25) . We have demonstrated that Lys 290 in Ti fl
is a critical residue. Site-directed mutagenesis of Lys 290 to
residues of conserved charge or conformation prevented sur-
face expression of Ti/CD3 (26) . This finding was confirmed
by Alcover et al . (27), who in addition, showed that at least
two Ti a mutants at Lys 290 (to Ala or Gln) could dimerize
with the a chain intracellularly, but association with CD3
was abrogated . Similarly, no surface expression of the TCR
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was obtained when Arg 121 and Lys 126 in the TM region
of Ti ci were altered by mutagenesis (28, 29). Interestingly,
the recent report by Blumberg et al . (29) showed that only
when both basic residues in the TM domain of Ti cx were
mutated was a(3 heterodimer formation andTCR/CD3 sur-
face expression blocked. Mutation of either the Arg to Gly
or Lys to Ile alone did not interfere with a or CD3 associa-
tion nor with the response ofthe resulting TCRto antibody
stimulation. Although mutations to other amino acids other
than Gly and Ile have not been tested and could possibly have
more deleterious effects, it appears that in the Ti a chain,
either one ofthe basic residues in theTM domain was sufficient
to allow interaction with theCD3 chains . These studies dem-
onstrate that these basic residues are required at their partic-
ular positions but provide little insight on their role in the
interaction between Ti and CD3.
To define the structural requirements for Ti/CD3 chain
association and signal transduction, chimeric Ti molecules
were constructed using the extracellular (EC) domain ofCD8oi
linked to the regions of Ti ot and a containing the TM do-
mains. CD8is a transmembrane protein expressed specifically
on the surface of T cells and, like Ti, exists as a dimer in
addition to its monomer and multimer forms (30) . Chimeric
CD8/Ti aand CD8/Ti /3 were transfected into a Jurkat mu-
tant that is deficient in endogenous Tio transcription and
as a consequence fails to express cell surface CD3. Our results
demonstrate that Ti is physically and functionally linked to
CD3 via the COOH termini containing their TM domains.
Materials and Methods
Cell Lines.
	
The human leukemic T cell lineJurkat (clone E6-1)
and its Tis-negative derivative, J.RT3T3.5, were maintained in
complete medium, which consists of RPMI 1640 supplemented
with 5% FCS, glutamine, penicillin G, and streptomycin (Irvine
Scientific) . Jurkat.CD8 (transfected with CD8a) was passaged in
complete medium containing Geneticin (Gibco Laboratories, Grand
Island, NY) at 1 mg/ml. J.RT3T3.5 was sequentially transfected
with the chimeric a and Q chain, and 10.23 is a transfectant that
expresses both chimeras.
Monoclonal Antibodies. The following mouse mAbs were used:
both OKT8 (American Type Culture Collection, Bethesda, MD)
and Leu-2A (Becton Dickinson Monoclonal Center, Mountain View,
CA) recognize external CD8 epitopes . Anti-Leu-4 (Becton Dick-
inson Monoclonal Center) is reactive with CD3. W6/32 recog-
nizes an invariant determinant expressed on human HLA class 1
antigens (31) . C305 is specific for Jurkat E6-1 Tis (19) . MOPC
195, an IgG2a, and MOPC 104E, an IgM (both from Litton Bio-
netics, Kensington, MD), were used as control antibodies in FACS®
analyses (Becton Dickinson & Co.) . Ascitic fluids of mAbs were
used at a final dilution of 1/1,000 (a saturating concentration) in
all experiments .
Construction and Expression of Chimeric Ti . The cDNAs and
amino acid sequences for Ti a and /3 (Jurkat) and CD8 a have
been described (30, 32, 33). The plasmid pSV7d-CD8a (gener-
ouslyprovided by Dan Littman, University ofCalifornia, SanFran-
cisco) contains the CD8 achain cDNA in the EcoRl site . A HindIII
site was introduced into the unique Nael site present near the TM
region of the CD8 cDNA by the insertion ofan 8-bp HindIII linker
(Boehringer Mannheim Biochemicals, Indianapolis, IN). Ti a
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cDNA contains a HindIII site near the TM region . The COON
terminus of CD8 (in pSV7d) from HindIII to EcoRI was replaced
by a 200-bp fragment of Ti a containing the TM and CYT do-
mains to generate CD8/Tics . This chimeric cDNA was cloned as
an EcoRI fragment into the vector SFFV.SVneo (a gift of Dennis
Loh, Washington University, St. Louis, MO) immediately 3' of
the Friend spleen focus-forming viral (SFFV) LTR. An XbaI-BamHI
fragment containing Ti 0 was excised from the plasmid pT/3Fneo
(20) and subcloned into pUC 19 . This subclone was linearized by
partial digestion with Eco109 and ligated with an adaptor con-
taining a HindIII site . Introduction of the HindIII site results in
valine 271 in the EC regionbeing substituted by leucine . However,
the translational reading frame is preserved in the final construct.
Plasmid pCD8/Tio was created by replacing the Ti /3 sequences
5' of the new HindIII site with the same CD8 EC segment used
in the chimeric aconstruct. Subsequently, an EcoRI-BamHI frag-
ment containing the SFFV long terminal repeat and CD8/Tio was
transferred into the expression vector pSV2gpt (34) .
The CD8/Tia and CD8/Ti/3 plasmids bearing selectable markers
for resistance to neomycin or mycophenolic acid were transfected
into cells by electroporation using a gene pulser (Bio-Rad Labora-
tories, Richmond, CA) at 300 Vand a capacitance of 500 p.F, with
20 ttg of plasmid DNA per 101 cells . Neo gene transfectants were
selected in medium containing Geneticin at 2 mg/ml. Gpt trans-
fectants were isolated by selection using xanthine (50 Ftg/ml), hypo-
xanthine (3 Etg/ml), and mycophenolic acid (1 .2 Rg/ml) . Xanthine
and hypoxanthine were purchased from Sigma Chemical Co. (St .
Louis, MO), and mycophenolic acid is from Calbiochem-Behring
Co . (La Jolla, CA).
Flow Cytometry. Cells were analyzedforexpression ofCD3and
the CD8 epitope by cell surface immunofluorescence techniques
as described (19) . For double staining, cells were stained directly
with FITC-Leu-2A and PE-Leu-4 . FITC- and PE-conjugated con-
trol mouse IgGs were used for background staining. Conjugated
mAbs were from Becton Dickinson & Co .
Northern Blot Analysis. Total RNAwas isolated from cells using
the guanidine thiocyanate method and centrifuged through a CsCl
cushion (35) . RNA (15 leg per lane) was separated electrophoreti-
cally on a 1% formaldehyde agarose gel and transferred to MSI
nylon (Fisher Scientific) . The "p-labeled probe was a 600-bp
cDNA fragment corresponding to the extracellular region ofCD8.
Surface Iodination and Immunoprecipitation . Cells were labeled
with I'll using lactoperoxidase/glucose oxidase (Sigma Chemical
Co.) as described (19) . The lysis buffer consists of 150 mM NaCl,
10 mM Tris-HCI, pH 7.8, with 1 mM PMSF and aprotinin (18
Ftg/ml) added as protease inhibitors together with either 1%
digitonin plus 0.12% Triton-X or 1% NP-40. Preclearing and
immunoprecipitation of cell lysates and analysis of proteins on
SDS-PAGE were performed as described previously (36) with the
following modifications. Rabbit anti-mouse IgG (Zymed Labora-
tories, So . San Francisco, CA)was bound to formalin-fixed Staphy-
lococcus aureus (Calbiochem-Behring Co.) and then armed with
normal mouse serum, OKT8, or anti-Leu-4 .
Inositol PhosphateAssay. Inositol phosphates (IPs) were quanti-
tated as described (37) . Cells loaded with ['HJmyo-Inositol were
incubated with mAb (1/1,000 dilution of ascites) or media as con-
trol, in the presence of 10 mM LiCl for 30 min at 37°C and then
lysed . Samples were performed in triplicate. IN were eluted from
an anion exchange resin column, and the amount oflabeled mate-
rial was determined by scintillation counting.
(Ca"], Measurement by Fluorimetry. Fluorimetry using indo-1
has been previously described (38) .
11,2 Bioassay. 24-well tissue culture dishes were coated with
rabbit anti-mouse Ig (Zymed Laboratories) at 100,ug/ml in car-
bonate buffer, pH 9.5 (15 mM Na2C03/35 mM NaHC03/0.02%a
NaN3). The wells were blocked with medium plus 10% FCS fol-
lowed by incubation with the appropriate mouse mAbs . Cells were
cultured in complete medium at a density of 3 x 106 cells/ml in
the coated culture dishes in the presence of PMA (10 ng/ml) or
PMA plus ionomycin (1 pM), for 24 h. Culture supernatants were
collected and assessed for 11,2 by the ability to support the growth
ofthe IIr2-dependent indicator cell line CTLIr2.20 using the MTT
colorimetric assay as described (39) .
Results
Construction andExpression ofthe CD8/Ti Chimeras.
	
Hybrid
Ti a and 0 chains were constructed by joining the CD8 a
chain EC domain to the COOH terminus of either Ti a
or a. Since the precise limits of the TM domains of the Ti
chains at the protein level have not been defined, chimeric
chains were constructed near the boundary of the Ti con-
stant region exon 3, which encodes the TM domain of Ti
a and both theTM and CYT domains of Ti a, respectively
(40, 41). Thus, these COON-terminal segments contain the
putative TM domain, the five amino acids of the CYT do-
main, as well as 14-16 residues of the Ti a and (3 EC do-
mains preceding the TM domain sequence . The amino acid
sequence at the cloning junction is shown in Fig. 1 A.
Figure 1 . Construction and expression ofthe CD8/Ti chimeric chains.
(A) Chimeric Ti chains were constructed bylinking the same cDNA frag-
ment encoding the EC region o£ CDS a to the COOH termini of Ti
a and /3 beginning at thejunction of constant region exon 3, which en-
codes the TM domain in each case. The amino acid sequences at the CD8
and Ti junction are shown. The number above each residue refers to its
position in the wild-type sequence. In the construction of CD8/Tif3, a
conservative change was made converting amino acid 271 in Ti/3 from
val to leu. (B) Northern blot analysis ofRNAfrom the parental and trans-
fected cell lines. Total RNA (15 Ftg per lane) was probed with a 32P-labeled
cDNA fragment corresponding to the CD8 EC domain . Lane 1, J.RT3-
T3.5 (Ti/6- mutant of Jurkat) ; lane 2, Jurkat; lane 3, Jurkat .CD8 ; lanes
4-6, J.RT3T3.5 transfected with chimeric CD8Ti a, CD8/Ti (3, or
CD8/Ti u plus CD8/Ti 0, respectively.
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The CD8/Tia and CD8/TiO plasmids were transfected
intoJ.RT3T3.5, a mutant ofthehumanT cell leukemic line
Jurkat, which fails to express theTCRcomplex due to deficient
endogenous Ti (3 chain transcription (20) . To determine if
the chimeras could form homodimers, since CD8 does exist
in homodimeric form, cells were transfected with single chi-
meric chains as well as with both chimeric chains in a se-
quential manner. In addition, wild-typeJurkat cells were trans-
fected with the full-length CD8 a chain cDNA to produce
the cell line Jurkat.CD8.
Expression of transcripts encoding the transfected chains
was assessed by Northern blot analysis of total RNAisolated
from representative transfectants. Jurkat and its 0 chain-
deficient derivative, J.RT3T3.5, are CD4+ lines and do not
express endogenous CD8 mRNA (Fig. 1 B, lanes 1 and 2) .
Jurkat.CD8 expressed CD8 amRNA (lane 3) . Both single
chimeric chain transfectants expressed high levels of the rele-
vant transcripts (lanes 4and 5) . The double transfectant, clone
Figure 2. Double immunofluorescence staining for cell surface CD8
and CD3. Cells were stainedwith FITC-conjugated anti-CD8 mAb (Leu-
2A) and PE-conjugated anti-CD3 mAb (anti-Leu-4) simultaneously and
analyzed byflow cytometry. As a negative control, cells were stained with
FITC- and PE-conjugated mousecontrol IgG. The panels are divided into
quadrants to define negative, single-positive, or double-positive cells.
10.23 (lane 6), expressed high levels of both chimeric tran-
scripts.
These six clonal cell lines in Fig. 1 B were analyzed for
surface expression of CD3 and the EC domain of CD8 by
double immunofluorescence staining with FITC-conjugated
anti-CD8 and PE-conjugated anti-CD3 mAbs (Fig. 2) . Jurkat
expressed high levels of CD3 only (Fig. 2 A) . In contrast,
the Tif3-negative mutant did not express surface CD3 or CD8
(Fig . 2 B) . The single chimeric chain transfectants that did
synthesize abundant chimeric mRNAs (Fig. 1 B) failed to
express surface CD8 (Fig . 1, C and D). Moreover, cell sur-
face expression of CD3 was not reconstituted in these cells.
The failure to detect CD8 and CD3 on screening multiple
single chimeric chain transfectants that were positive at the
RNA level suggest that the individual chimeric chain be-
haved more like individual wild-type Ti chains than CD8
in their requirements for surface expression and did not form
homodimers. However, when both chimeras are expressed
in a single cell, as in clone 10.23, not only were CD8 anti-
genic determinants expressed, but surface CD3 was restored
as well (Fig. 2 E) . Expression of the CD8 and CD3 deter-
minants on 10.23 was stoichiometric, suggesting that they
are expressed on the same molecular complex . In compar-
ison, Jurkat.CD8 did not demonstrate this linear relation-
ship (Fig . 2 F) since wild-type CD8 is expressed indepen-
dent of CD3 in this transfectant as it is in other cells that
normally express CD8. These results suggest that the chi-
meric CD8/Ti receptor is expressed as a heterodimer that
is physically associated with CD3.
Physical Association of CD8/Ti and CD3 .
	
To determine
if the chimeric CD8/Ti receptor is physically linked to the
CD3 complex, two additional lines ofinvestigation were used.
The TCR complex is internalized in response to soluble antiTi
or anti-CD3 mAbs (14) . Therefore, it was of interest to de-
termine whether the CD8/Ti chimeric receptor would coin-
ternalize with CD3. Cells were incubated for 16 h at 37°C
in the presence or absence of an anti-CD3 mAb (anti-Leu-4),
and then stained by indirect immunofluorescence for CD3,
CD8, and Ti expression . mAb C305 specifically detectsJurkat
Ti 0. Untreated clone 10.23 did not stain with C305, verifying
that this clone has a a chain-negative background (Fig . 3) .
Pretreatment with anti-Leu-4 resulted in diminished expres-
sion of both CD3 and the CD8 determinant on clone 10.23 .
With Jurkat.CD8, Ti and CD3 cointernalized after anti-CD3
treatment but the expression of CD8 was not affected .
Further evidence that the chimeras are physically coupled
to CD3 was the ability of the two complexes to coim-
munoprecipitate with either anti-CD8 or anti-CD3 mAb .
Surface radioiodinated cells were solubilized in NP-40, in which
CD8 is more soluble (Fig. 4 A), or in digitonin buffer (Fig.
4, B and C), which preserves the Ti/CD3 association . From
NP-40 lysates of 10.23, anti-CD8 immunoprecipitated the
chimeric chains of27 and 28 Mconsistent with the predicted
molecular masses ofCD8/Ti ot and a (Fig. 4 A). In NP-40,
these bands were immunoprecipitated independent of CD3.
Under nonreducing conditions, the chimeric chains were im-
munoprecipitated as disulfide-linked dimers (data not shown) .
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Figure 3. Comodulation ofCD8/Ti and CD3 with anti-CD3 antibody.
Cells were incubated for 16 h at 37°C with anti-CD3 (anti-Leu-4) ascites
(1:1,000 dilution) or with no antibody (control) . Cells were stained for
CD3, CD8, or Ti with the appropriate mAb (anti-Leu-4, OKT8, and
C305, respectively) using FITC-conjugated goat anti-mouse Ig as second
antibody and then analyzed on a FACScan® flow cytometer (BectonDick-
inson & Co.). The left histogram in each panel represents as a negative
control cells stained with a nonreactive mouse Ig.
From Jurkat.CD8, anti-CD8 immunoprecipitated only a
32-kD band corresponding to the CD8 monomer (Fig. 4 A),
which has a mobility similar to that of the CD3 y chain.
Although Ti chains did coprecipitate with CD3 from Jur-
kat.CD8 in this experiment using NP-40, more reliable
coprecipitation is generally obtained using lysates prepared
in digitonin . In digitonin buffer, both anti-CD8 and anti-
CD3 immunoprecipitated identical proteins consisting of the
chimeric chains as well as the CD3 complex of molecular
mass range of 20 to 30 kD from 10.23 lysates (Fig. 4, B and
C) . The CD3 pattern in 10.23 differs from that inJurkat.CD8.
On further analysis, it was found that the S chain in 10.23
has reduced mobility and migrates as a broad band partly
buried within the 28-30-kD CD3 y chain . This difference
in mobility is most likely due to a difference in glycosyla-
tion, based on studies with a CD3 S chain-specific antibody
(data not shown) . The chimeric disulfide-linked dimer seen
under nonreducing conditions (Fig. 4 C) is consistently ob-
served as a band of -45 kD in repeated experiments. Thus,
the chimeric ci and # chains are disulfide linked . but migrate
anomalously under nonreducing conditions.
In contrast to the studies with the 10.23 cell line, anti-
CD3 and anti-CD8 immunoprecipitates from the Jurkat.CD8
clone were strikingly different . Anti-CD3 mAb precipitated
the wild-type Ti chains (the 40-49-kD bands) as well as the
y (28-30 W), 6 (23 kD), and e (22 W) chains of CD3,
but not CD8 (Fig. 4 B and C) . This CD3 immunoprecipi-
Figure 4 .
	
Coitnmunoprecipitation of surface CD8/Ti and CD3. Cell surface proteins were labeled with 1251 and the cells lysed in 1% NP-40 buffer
(A), or in 1% digitonin lysis buffer (B and C), which preserves the Ti/CD3 association . Cell lysates were immunoprecipitated with normal mouse
serum (NMS), anti-CD8 (OKT8), or anti-CD3 (Leu-4) mAb. Immunoprecipitates were analyzed on 10% SDS-PAGE under reduced (A and B) or
nonreduced (C) conditions. Wild-type (WT) Ti, CD8/Ti, CD3, and the positions of the relative molecular mass standards (in kD) are indicated .
tate is identical to those that have previously been shown from
this laboratory using wild-type Jurkat cells that do not ex-
press CD8 (8, 38) . In the CD3 immunoprecipitate of the
Jurkat.CD8 lysate (Fig . 4 B), the two highestbands migrating
at 45 and 49 kD correspond to different glycosylated forms
of Ti a, as was shown in previous studies, and the lowest
of the three bands is Ti ß. None of the Ti or the CD3 chains
were visualized in immunoprecipitates preserved with the anti-
CD8 mAb (Fig. 4 B and C) in five separate experiments . Note
that the 28-kD faint band seen under reducing conditions
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in the anti-CD8 immunoprecipitate migrates as a faint diffuse
band with higher apparent molecular mass under nonreducing
conditions and therefore represents CD8 (compare OKT8
lanes in panels B and C) . CD8 apparently has low solubility
in digitonin. Collectively, these results demonstrate that the
CD8/Ti chimera is physically associated with CD3 on 10.23
but that normal CD8 does not similarly interact with CD3
on Jurkat.CD8 .
Functional Coupling ofCD8/Ti to CD3. Having demon-
strated that the COOH termini ofTi cx and Ti ß containing
Figure 5. Inositol phosphate generation
upon stimulation of the chimeric receptor. Cells
loaded with [3 H]myo-inositol were incubated
with or without (control) mAb for 30 min at
37°C in the presence of LiCl, and then lysed.
Water-soluble [3H]inositol phosphates were
extracted and counted.
the TM domains sufficient for the chimeric receptor associa-
tion with CD3, we next determined if this structural coup-
ling to CD3 also resulted in a functional interaction between
the chimeric receptor and CD3. mAbs reactive with Ti or
CD3 but not CD8 can mimic the effects of antigen and serve
as agonists to stimulate signal transduction events as well as
cellular activation responses (9) . The ability of the CD8/Ti
receptor to transduce signals via the phosphatidylinositol
pathway upon stimulation with agonistic mAbs was assessed .
The generation of inositol phosphates upon stimulation with
anti-CD8 and anti-CD3 was assessed in 10.23 andJurkat.CD8
(Fig. 5) . 10.23 could be stimulated by both anti-CD8 and
anti-CD3 to increase inositol phosphate levels to 370 ± 11%
and 537 ± 11% of unstimulated cells, respectively. This re-
sponse was specific since W6/32, an antibody to MHC class
1, failed to induce increases in inositol phosphates . In con-
trast, Jurkat.CD8 responded normally to anti-CD3 but failed
to respond well to anti-CD8, even though it expressed four-
to fivefold more CD8 than the chimeric CD8/Ti receptor
on 10.23 . The smaller increase ofinositol phosphates observed
in 10.23 in response to anti-CD3 can be attributed to its lower
level of CD3 expression (threefold lower than Jurkat.CD8 ;
see Fig. 3) since the magnitude of inositol phosphate genera-
tion is directly related to the level of TCRs engaged on other
cells (Graber, Bockenstedt, and Weiss, unpublished obser-
vations) .
C
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Induction of [Ca 2+ ]i increase . Cells loaded with indo-1 were
stimulated with OKT8 or anti-Leu-4 ascites (1:1,000 dilution) and ana-
lyzed for [Ca2+]i changes by fluorimetry. To ensure proper loading of the
cells with the indo-1 fluorescent dye and releasability of Ca2+ stores, cells
were treated with 114M ionomycin. Arrows indicate the addition ofmAb
or ionomycin.
100
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As a consequence of the generation ofinositol phosphates
in T cells, increases in cytoplasmic free calcium ([Ca2+]) are
observed (37) . To measure calcium responses, 10.23 and
Jurkat.CD8 were loaded with indo-1, a calcium-sensitive
fluorescent dye, and stimulated with mAbs. Changes in
[Ca2+]; were monitored by fluorimetry. In 10.23, anti-CD8
induced a rapid and large rise in [Ca2+];, with a peak re-
sponse of609 nM over baseline (Fig. 6 A) . Only a very small
increase in [Ca2+]i was observed with Jurkat.CD8 in re-
sponse to anti-CD8 (C) although the cells were capable of
responding normally to anti-CD3 (D) . The small increase
in [Ca2 +] ; in Jurkat.CD8 was only observed at the highest
concentration of anti-CD8 used .
As a final assay for chimeric CD8/Ti receptor function,
these cells were tested for Ilr2 production in response to
stimulating mAbs. Jurkat.CD8 and 10.23 cells were stimu-
lated for 18-24 h with mAb plus PMA. PMA is required
for TCR-induced 11,2 production in Jurkat cells (42) . The
culture supernatants were harvested and assessed for 11,2 con-
1/Dilution
--a- anti-CD8
anti-CM
-t anti-Ti
f lonomycin
Figure 7 . Induction of11,2 production. (A) 10 .23 and (B) Jurkat.CD8
cells were stimulatedwith the mAbs C305 (antiTi) (" ), anti-Leu-4 (anti-
CD3) (A), or OKT8 (anti-CD8) (/), or with ionomycin (1 /M) (*),
all in the presence of PMA (10 ng/ml) . IL2 secretion was determined by
the ability of culture supernatants of stimulated cells to support the growth
ofCTLI,20 indicator cells as assessed in the MTTcolorimetric assay. Sur-
vival ofthe indicator cell is proportional to the absorbance at 570 nm in
this assay. Results were normalized to the maximal response in this assay.
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tent by their ability to support the growth of CTLIr20, an
IIr2-dependent cell line. Clone 10.23 produced 11,2 in re-
sponse to either anti-CD8 or anti-CD3 (Fig. 7 A) . mAb C305
served as a negative control since 10.23 lacks Ti /3 . In con-
trast, anti-CD8 did not induce IL2 production byJurkat.CD8,
although these cells were capable ofresponding to either C305
or anti-Leu-4 (Fig. 7 B) . In contrast to previous studies with
Jurkat cells or withJurkat.CD8, immobilization of mAb was
required to induce IL2 production by 10.23 . We presume
that mAb in solution did not stimulate IL2 production in
10.23 because of the lower number ofTCRs that are expressed
on 10.23 and that a proportion of these receptors are inter-
nalized in response to stimulation with soluble mAbs. 10.23
expresses threefold fewer receptors than Jurkat.CD8 as deter-
mined by flow cytometry analysis (also see Fig. 3) . Note that
the potential of these two cells to produce IL2, as measured
by their maximal responses to the calcium ionophore iono-
mycin plus PMA, also differs. Although 10.23 produces sub-
stantially less IL-2 than Jurkat.CD8, 10.23 produced nearly
maximal levels of 11,2 when the CD8/Ti chimeric receptor
was stimulated . Collectively, our results demonstrate that the
CD8/Ti chimeric receptor is functionally coupled to the CD3
complex .
Discussion
As a first step towards determining the region essential
for Ti and CD3 association and function, we have constructed
a chimeric TCR with the COON-terminal regions of Ti a
and 0 linked to the EC domain of CD8, a T cell-specific
surface glycoprotein. Here, we demonstrate that expression
of both chimeric chains restores CD3 plasma membrane ex-
pression on a mutant of the T cell leukemic line Jurkat that
lacks functional endogenous Tif3 transcripts. In addition to
defining domains ofthe Ti a and (3 chains involved in struc-
turally linking Ti to CD3, these domains were shown to func-
tionally link Ti to signal transduction mechanisms associated
with CD3. These studies support the role of CD3 in medi-
ating TCR transmembrane signaling .
Although CD8 can form homodimers on T cells and on
fibroblasts (30), transfection ofCD8/Tia or CD8/Tio alone
did not reconstitute surface expression of CD3, nor was the
CD8 epitope detected by mAb OKT8 by FACS® analysis.
Thus, the chimeras behaved more like the individual wild-
type Ti chains than CD8 since they did not form homodimers.
This suggests that the COON-terminal domains of CD8 and
Ti are not interchangeable . In addition, heterodimers of
CD8/Ti a and endogenous Ti a were not expressed, indi-
cating that the EC domains do influence Ti a and Ti (3 as-
sociation. The EC region ofTi a is composed of two Ig-like
domains and is much larger (232 amino acids) than the EC
region of CD8 (150 amino acids), which contains only a single
Ig-like domain . The different EC domains may not be com-
patible, possibly due to steric hindrance.
We found that both chimeric chains were required to ex-
press the chimeric Ti and to restore CD3 onto the cell sur-
face. Moreover, this association between the chimeras and
CD3 showed a stoichiometric relationship. That the two com-
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plexes were physically linked was confirmed by their ligand-
induced cointernalization and their coimmunoprecipitation .
The chimeric chains formed interchain sulfhydryl bonds, pre-
sumably through cys 143 from the EC domain of CD8, the
only cysteine that is not in the Ig-like fold . The cysteines
in Ti a and (3 that are thought to be responsible for inter-
chain disulfide linkages were eliminated in the construction
of the chimeras.
Our data demonstrate that the physical association between
CD3 and the CD8/Ti chimeras resulted in a functional in-
teraction as well . The chimeric CD8/Ti could effectively
transmit signals for T cell activation through the phosphati-
dylinositol pathway that is coupled to CD3. Anti-CD8 mAb
was able to induce an increase in inositol phosphates and a
large rise in [Ca2 +] ;, as well as IL2 production through the
chimeric receptor but not through wild-type CD8 . Thus,
by linking the EC domain of CD8 to the COON termini
of the Ti a and a chains, a functional interaction with CD3
was established . These data are consistent with the notion
that the role ofCD3 is to couple ligand-occupied Ti to intra-
cellular signaling mechanisms .
These studies have defined a region within the COOH
termini of Ti ct and (3 that contains all of the information
required for structurally and functionally coupling the chi-
meric CD8/Ti to the CD3 complex . It is possible that the
TM domains alone contained within the COON-termini seg-
ments of Ti can mediate this association between CD8/Ti
and CD3. It is less likely that the 14 and 16 amino acids ex-
tracellular to the putative published TM domains or the five
amino acids of the CYT domains ofboth Ti chains contained
in these chimeric constructs contribute to the association with
the CD3 complex and signal transduction. Ti y/b is also
structurally and functionally associated with CD3 although
its antigenic specificity is poorly understood . A comparison
of the COON termini of Ti a, /3, y, and b chains reveals
little amino acid identity among the four chains in these EC
and CYT regions, particularly in the comparison of /3 to y
and ot to b. In contrast, the predicted TM domains of Ti
u and Ti b are highly conserved (43, 44) . Conservation of
the sequences of the TM domains is also noted in the Ti /3
chain in chicken, whereas little homology is found in these
EC and CYT regions (Craig Thompson, personal commu-
nication) . One difficulty of studying subunit interactions of
an oligomeric complex such as the TCR can be circumvented
by studying the interaction in fibroblast cells that do not syn-
thesize any of the TCR components . Although the physical
interactions identified cannot be accompanied by functional
studies, this system allows the dissection ofa complex receptor
into smaller units whose interactions could provide clues on
how the whole complex is assembled. By transfecting pairs
of TCR chains into COS cells, Manolios et al. (45) demon-
strated that Ti a associated with CD3 b, and not y or r
By constructing a series of chimeric proteins using the Tac
antigen fused to variable amounts ofTi a TM and CYT do-
mains, they were able to narrow down to a stretch of eight
residues, including the two basic residues within the puta-
tive TM domain of ct, that still permitted assembly with b .
Consistent with earlier reports, elimination of the two basic
residues in the TM region of cx abolished association with
S . Replacement of the five CYT residues of a with sequences
from Tac had no effect on the association with S, but replace-
ment of the TM region eliminated that association . Their
findings are consistent with our data that point to the TM
domain as being essential for physically and functionally coup-
ling Ti to CD3. Our study is an initial step towards defining
a minimal sequence involved in the Ti/CD3 interaction . Con-
struction of additional chimeras currently underway and site-
directed mutagenesis within the COOH-terminal regions of
both Ti and CD3 would provide further insight into their
interaction and perhaps elucidate the mechanism of signal
transfer from ligand-bound Ti to CD3 and the associated in-
tracellular signal transduction pathways.
There are two models to explain the functional coupling
of CD8/Ti chimeric chains to signal transduction mecha-
nisms in our studies. Upon ligand binding, Ti undergoes a
conformational change that is transmitted via the COON
terminus to CD3 . CD3 is then induced, presumably through
allosteric changes, to activate the intracellular signaling mech-
anisms. Alternatively, the bivalent mAbs used as stimuli may
be crosslinking CD3 complexes by interacting with the as-
sociated CD8/Ti chimera, and it is this effect ofaggregation
that initiates the cascade of signaling events. In theory, the
use of monovalent Fab fragments could address this ques-
tions. However, the inherent problems with Fabs, such as
diminished avidity and aggregation at high concentrations
that are necessary to mimic the effects produced by bivalent
antibodies, precludes their usage in attempting to distinguish
between the two models .
Another approach to studying chain interaction in a multi-
subunit complex is through the use of synthetic peptides cor-
responding to particular domains ofa subunit. Synthetic pep-
tides corresponding to the TM domains of glycophorin A
were shown to complex specifically with native glycophorin
A chains in an in vitro bilayer system (46) . This interaction
References
was not inhibited by synthetic peptides of the TM domains
of glycophorin C or the Ilr2R Tac protein, which were similar
in amino acid composition to that of glycophorin A. Thus,
there is precedent for the TM domains of at least one other
plasma membrane oligomer, albeit a dimer, in mediating in-
terchain associations .
In the assembly of the complete TCR complex, the ~ chain
is the limiting component, at least in the murine T cell line,
2134. The other five chains (ot, (3, 6, y, and e) are synthesized
in vast excess (47) . These excess chains form pentamers within
the endoplasmic reticulum (ER). A fraction of the pentamers
then assemble into heptamers with the available ~ Both pen-
tamers and heptamers are efficiently transported out of the
ER and into the Golgi apparatus, but from there only hepta-
meric complexes reach the cell surface (22) . All other com-
plexes are rapidly destroyed. It was shown that in T cells,
a chains associated with (3 and the CD3 ~ybe chains were
destroyed in lysosomes (48) . In fibroblasts, however, degra-
dation offree ci chains occurred by an ER pathway. The re-
gion that targets unassembled ot chains for retention and rapid
degradation was recently localized to the TM domain of the
a chain (49) . These experiments and those reported here dem-
onstrate that TM domains can contain not only the struc-
tural information for the insertion and anchoring of a pro-
tein in the membrane, but also sites for interaction with other
subunits ofa complex and, apparently, signals for degradation .
These studies have provided the first evidence to suggest
that the regions surrounding and including the TM domains
of an oligomeric plasma membrane receptor, the TCR, are
involved not only in structural but also functional interac-
tions between subunits of the receptor. The experimental ap-
proach used here should be applicable to other oligomeric
receptor systems. Now that a region responsible for has been
defined in the interaction between Ti and CD3, it should
be possible to more precisely understand their structural and
functional interactions .
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